CLAIM CARD
Mechanistically, the rationale for aspirin's potential geroprotective action on frailty would involve its anti-inflammatory and antiplatelet properties, which could theoretically modulate the chronic low-grade inflammation (inflammaging) associated with sarcopenia and functional decline. However, the clinical RCT evidence from ASPREE does not support this pathway translating into a functional benefit for frailty reversal. The disconnect between plausible biological mechanisms and the observed null clinical outcome underscores the complexity of targeting multifactorial age-related syndromes with a single pharmacological agent.
Evidence grade: exploratory
Contradiction status: none
Publication: 4ff5f065-8b09-4580-9cbc-da14dbcaa1fa
Provenance: Derivation Web chain
Citation Support
source_1Flensted-Jensen 2025source_2Saeed 2026source_3Zhu 2026source_4Navarese 2026source_5Yan 2024